Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Locations
- 🇫🇷
Centre D'Oncologie Du Pays-Basque, Bayonne, France
🇫🇷Hopital Intercommunal De Creteil, Creteil, France
🇫🇷Centre Hospitalier d'Antibes, Antibes, France
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT00031629
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT00042939
Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT00021242
- Locations
- 🇺🇸
General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, United States
🇺🇸Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 263
- Registration Number
- NCT00047255
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-01-10
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 27
- Registration Number
- NCT00041093
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- International Collaborative Cancer Group
- Registration Number
- NCT00010140
- Locations
- 🇬🇧
Charing Cross Hospital, London, England, United Kingdom
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-08-28
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT00014456
- Locations
- 🇺🇸
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
- Conditions
- First Posted Date
- 2003-01-15
- Last Posted Date
- 2011-10-24
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00051571
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Virginia Mason Research Center, Seattle, Washington, United States
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2002-11-27
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 603
- Registration Number
- NCT00050167
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.